Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 2913-2920

  Hsueh, Eddy C ^a   Gupta, Rishab K ^a   Qi, Karen ^a   Morton, Donald L ^a,b  

^a SAINT JOHN'S HEALTH CENTER   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CANCER VACCINE; MELANOMA VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031713904     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.2913     Document Type: Article

References (35)

1. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastasis. J Am Coll Surg 181:193-201, 1995
2. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 71:2995-3005, 1993
3. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of melanoma. IV: Prognostic factors in 200 melanoma patients with distant metastasis (stage IV). J Clin Oncol 1:126-134, 1983
4. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
5. Morton DL, Foshag LJ, Hoon DSB, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
6. Livingston PO, Wong GYC, Sucharita A, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994
7. Jones PC, Sze LL, Liu PY, et al: Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen (OFA-1). J Natl Cancer Inst 66:249-254, 1981
8. Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic melanoma. N Engl J Med 313:1485-1492, 1985
9. Dorval T, Palangie T, Jouve M, et al: Clinical phase II trial of recombinant DNA interferon (interferon alpha-2b) in patients with metastatic melanoma. Cancer 58:215-218, 1986
10. Legha SS, Papadopoulos NE, Plager C, et al: Clinical evaluation of recombinant interferon alpha-2b (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5:1240-1246, 1987
11. Robinson WA, Mughal TI, Thomas MR, et al: Treatment of metastatic malignant melanoma with recombinant interferon alpha-2. Immunobiology 172:275-282, 1986
12. Parkinson DR, Abrams JS, Wiernik PH, et al: IL-2 therapy in patients with metastatic malignant melanoma: A phase II study. J Clin Oncol 8:1650-1656, 1990
13. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 319:1676-1680, 1988
14. Dutcher JP, Creekmore S, Weiss GR, et al: A phase II trial of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477-485, 1989
15. Ferrone S: Human tumor-associated antigen mimicry by anti-idiotypic antibodies: Immunogenicity and clinical trials in patients with solid tumors. Ann NY Acad Sci 690:214-224, 1993
16. Berd D, Maguire HC Jr, Mastrangelo MJ: Treatment of human melanoma with a hapten-modified autologous vaccine. Ann NY Acad Sci 690:147-152, 1993
17. Mitchell MS, Harel W, Kan-Mitchell J, et al: Active-specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results, and possible mechanisms of action. Ann NY Acad Sci 690:153-166, 1993
18. Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244, 1996
19. Nabel GJ, Gordon D, Bishop DK, et al: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93:15388-15393, 1996
20. Morton DL, Hoon DSB, Foshag LJ, et al: Active immunotherapy of metastatic melanoma with melanoma vaccine immunomodulation. Proc Am Assoc Cancer Res 32:492, 1991 (abstr)
21. Morton DL, Foshag LJ, Nizze JA, et al: Active specific immunotherapy in malignant melanoma. Semin Surg Oncol 5:420-425, 1989
22. Morton DL, Hoon DSB, Nizze JA, et al: Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann NY Acad Sci 690:120-134, 1993
23. Hsueh EC, Nizze A, Essner R, et al: Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases: Matched pair analysis. Proc Am Soc Clin Oncol 16:492a, 1997 (abstr)
24. Overett TK, Shiu MH: Surgical treatment of distant metastatic melanoma: Indications and results. Cancer 56:1222-1230, 1985
25. Feun LG, Gutterman J, Burgess MA, et al: The natural history of resectable metastatic melanoma (stage IVA melanoma). Cancer 50:1656-1663, 1982
26. Karakousis CP, Velez A, Driscoll BA: Metastasectomy in malignant melanoma. Surgery 115:295-302, 1994
27. Euhus DM, Gupta RK, Morton DL: Detection of a tumor-associated glycoprotein antigen in serum and urine of melanoma patients by murine monoclonal antibody (AD1-40F4) in enzyme immunoassay. J Clin Lab Anal 3:184-190, 1989
28. Euhus DM, Gupta RK, Morton DL: Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 45:1065-1070, 1990
29. Euhus DM, Gupta RK, Morton DL: Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 29:247-254, 1989
30. Gupta RK, Morton DL: Monoclonal antibody based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J Clin Lab Anal 6:329-336, 1992
31. MacLean GD, Reddish MA, Koganty RR, et al: Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59-68, 1996
32. Ollert MW, David K, Schmitt C, et al: Normal human serum contains a natural IgM antibody cytotoxic for human neuroblastoma cells. Proc Natl Acad Sci USA 93:4498-4503, 1996
33. Barth A, Hoon DSB, Foshag LJ, et al: Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54:3342-3345, 1994
34. Hunt KK, Shibata M, Gupta RK, et al: Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigen. Cancer Immunol Immunother 34:377-382, 1992
35. Uchiyama A, Hoon DS, Morisaki T, et al: Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response. Cancer Res 53:949-952, 1993